note the omission of the word "invest" in Sareptas other recent announcements; something there? time will tell...
As we track out of 2021 and into a milestone-rich 2022, we are delivering on our approved therapies, seeing successes across our programs, and as of today, with greater than $2 billion of cash and cash equivalents on our balance sheet and a first-in-class team of genetic and rare disease professionals, have the resources and talent to deliver on the promise of our multi-platform pipeline.”
ANP Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
